Meeting Banner
Abstract #4700

The Neurobiology of Placebo Response in Adolescents with Generalized Anxiety Disorder

Lu Lu1,2, Hailong Li1, Jeffrey Mills3, Heidi Schroeder2, Sarah Mossman2, Sara Varney2, Kim Cecil4, Melissa DelBello2, Amir Levine5, Xiaoqi Huang1, Qiyong Gong1, John Sweeny1,2, and Jeffrey Strawn2
1Huaxi MR Research Center (HMRRC), Functional and molecular imaging Key Laboratory of Sichuan Province,Department of Radiology, West China Hospital of Sichuan University, Chengdu, China, 2Department of Psychiatry and Behavior Neuroscience, College of Medicine, University of Cincinnati, Cincinnati, OH, United States, 3Carl H. Lindner College of Business, University of Cincinnati, Cincinnati, OH, United States, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States, 5Division of Child and Adolescent Psychiatry, Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, United States

Increasing placebo response rates represent a significant barrier to detecting treatment effects in pediatric psychiatry clinical trials. To identify biomarkers for it in adolescents with generalized anxiety disorder prior to their entering a clinical trial, whole brain dynamic and static functional connectivity (FC) were used. Dynamic and static FC between the amygdala, dorsal anterior cingulate cortex, ventrolateral prefrontal cortex and regions that subserve emotion control and inhibition were significantly associated with degree of placebo response and differed between placebo responders and non-responders. These findings may be used to decrease placebo response in clinical trials to more effectively evaluate novel treatments.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here